Neurana Pharmaceuticals Announces Completion of $60 Million Series A Financing Funding to advance novel drug for acute, painful muscle spasms and spasticity without sedation SAN DIEGO, California May 7, 2018 – Neurana Pharmaceuticals, Inc., a specialty pharmaceutical...
Preclinical Data Demonstrate That Deciphera Pharmaceuticals’ DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents...
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson’s Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018 Evanston, Ill., March 15, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative...
by Jeff Fryer | Apr 24, 2018 Rallybio Completes $37.0M Series A Financing Rallybio Established by Industry Leaders with $37.0 Million in Series A Financing to Develop Transformative Therapies for Patients with Severe and Rare Diseases FARMINGTON, CT, April 25, 2018 –...
Recent Comments